Indoco Remedies

Indoco Remedies Enterprise Value

The Enterprise Value (EV) of Indoco Remedies (INDOCO.NS) as of Oct 16, 2026 is 29.11 B INR. In the previous year, Enterprise Value (EV) was 28.45 B INR — a change of 2.31% (higher).

Enterprise Value

29.11 BINR

YoY

2.31%

Last updated:

Enterprise Value (EV) of Indoco Remedies is 2026 29.11 B INR. Enterprise Value (EV) of Indoco Remedies was 2025 28.45 B INR. It decreases by 2.31% higher compared to the previous year.

The Indoco Remedies Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
21.34 B INR
Jan 1, 2020
21.09 B INR
Jan 1, 2021
21.22 B INR
Jan 1, 2022
20.82 B INR
Jan 1, 2023
21.88 B INR
Jan 1, 2024
25.16 B INR
Jan 1, 2025
28.45 B INR
Jan 1, 2026
29.11 B INR
The Indoco Remedies Enterprise Value history
YEAREnterprise ValueYoY
29.11 BINR+2.31%
28.45 BINR+13.05%
25.16 BINR+15.04%
21.88 BINR+5.09%
20.82 BINR-1.89%
21.22 BINR+0.62%
21.09 BINR-1.18%
21.34 BINR-0.25%
21.39 BINR+4.78%
20.42 BINR+3.93%
19.65 BINR+1.29%
19.39 BINR+0.75%
19.25 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Enterprise Value (EV) of Indoco Remedies is 29.11 B INR in 2026.

Enterprise Value (EV) of Indoco Remedies changed from 28.45 B INR to 29.11 B INR, representing a 2.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s INR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' INR varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Indoco Remedies

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Indoco Remedies